GSK_ Annual_Report_2021-22

NOTES TO THE FINANCIAL STATEMENTS for the year ended March 31, 2022 195 2 The following transactions were carried out with the related parties at normal commercial terms in the ordinary course of business. Holding Company Year Ended March 31, 2022 Year Ended March 31, 2021 GlaxoSmithKline Pharmaceuticals Limited 1. Payment of common costs 61.46 25.33 2. Sale of products 6,65.55 3,23.43 3. Payment of Manufacturing charges 13,03.40 3,94.87 4. Interest on loan taken 44.80 - 5. Borrowings 14,60.00 - 6. Outstanding receivable / (Payable) by the Company (net)* (4,18.28) (3,94.16) Other related parties in the GlaxoSmithKline (GSK) Group where common control exists Year Ended March 31, 2021 ** Year Ended March 31, 2022 Year Ended March 31, 2021 GSK Asia Private Limited GSK Export Limited 1. Purchase of raw materials 10,52.62 - 2. Sale of products - 74,00.45 9,32.79 3. Outstanding receivable / (Payable) by the Company (net)* - 12,96.32 10,44.72 * Transactions with the above parties are accounted in the respective current accounts. ** No transactions for the year ended March 31, 2022 Note 30 : Disclosures as required by Micro, Small and Medium Enterprises Development Act, 2006 are as under: ( ` in lakhs) As at March 31, 2022 As at March 31, 2021 (a) The principal amount and the interest due thereon remaining unpaid to suppliers (i) Principal 17.69 - (ii) Interest due thereon 0.63 - 18.32 - (b) (i) The delayed payments of principal amount paid beyond the appointed date during the entire accounting year 1,23.43 - (ii) Interest actually paid under Section 16 of the Micro, Small and Medium Enterprises Development Act, 2006 - - (c) (i) Normal Interest accrued during the year, for all the delayed payments, as per the agreed terms - - (ii) Normal Interest payable for the period of delay in making payment, as per the agreed terms - - (d) (i) Total Interest accrued during the year 0.63 - (ii) Total Interest accrued during the year and remaining unpaid 0.63 - The above information regarding Micro, Small and Medium enterprises has been determined to the extent such parties have been identified on the basis of information available with the Company.